Potential use of HMG-CoA reductase inhibitors (statins) as radioprotective agents

Area of Science:

• Biochemistry
• Molecular Biology
• Radiology

Background:

• HMG-CoA reductase inhibitors (statins) are primarily used to treat hypercholesterolemia.
• Statins exhibit pleiotropic effects beyond lipid reduction, including the inhibition of Ras-homologous (Rho) GTPases.
• Radiotherapy can cause significant normal tissue damage, necessitating radioprotective strategies.

Purpose of the Study:

• To explore the potential of statins as radioprotective agents.
• To investigate the effects of statins on radiation-induced inflammation, fibrosis, and DNA damage.
• To evaluate the impact of statins on DNA repair mechanisms post-irradiation.

Main Methods:

• In vitro studies assessing mRNA expression of cytokines in response to ionizing radiation (IR).
• In vivo studies evaluating IR-induced inflammation and fibrosis.
• Analysis of DNA double-strand break repair and DNA damage response modulation by statins.
• Assessment of in vivo mRNA expression of DNA repair factors.

Main Results:

• Statins reduced pro-inflammatory and pro-fibrotic cytokine mRNA expression stimulated by IR in vitro.
• Statins alleviated IR-induced inflammation and fibrosis in vivo.
• Statins accelerated DNA double-strand break repair and mitigated the DNA damage response induced by IR.
• Statins increased the mRNA expression of DNA repair factors in vivo.

Conclusions:

• Preclinical data suggest statins possess a promising radioprotective capacity.
• Statins may protect normal tissues from radiotherapy-induced damage by modulating inflammatory and fibrotic pathways.
• Statins appear to enhance DNA repair mechanisms, contributing to their radioprotective effects.